In Memoriam: Jack Kavanagh, co-founder of AzMN

John Thomas (Jack) Kavanagh, co-founder of the Arizona Myeloma Network (AzMN), passed away on Saturday, May 25, 2024 at the age of 87.  Diagnosed with Multiple Myeloma in 1991, Jack had a successful business career prior to retiring to Arizona in 2003 and creating AzMN with his wife Barbara in 2004.

Continue reading

Heard at BIO2024: Arizona is Amazing

The world biotechnology community converged in San Diego on June 3-6, 2024  for the BIO International Convention.  As of Monday morning over 18,500 people were registered to attend and over 60,000 partnering meetings had been scheduled. Arizona's health innovation community was well represented.  Joan Koerber-Walker, President & CEO of AZBio, spoke with investors, companies, family offices, industry leaders, and international organizations  to share what's happening in Arizona. In meeting after meeting and from conversation to conversation a theme emerged - what's happening in Arizona  is amazing.

Continue reading

The Foundation for the National Institutes of Health Announces the Launch of a Public-Private Partnership to Accelerate ALS Diagnosis and Treatment

  • The Foundation for the National Institutes of Health Announces the Launch of a Public-Private Partnership to Accelerate ALS Diagnosis and Treatment
  • The Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS) will create the largest open data platform for ALS research
  • Partnership will enable discovery and development of diagnostic tools, biomarkers, and better treatments

Managed by the FNIH, the Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS) brings together the resources and expertise of the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), the Food and Drug Administration (FDA), Critical Path Institute (C-Path), and other stakeholders from academia, life science companies, foundations, and patient-focused groups to tackle the tremendous challenges of diagnosing, understanding, and treating the disease. AMP ALS is supported by a combined commitment of approximately $60 million.Continue reading